Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced ...
Healio

Non-pharmacological therapy may benefit hand function in systemic sclerosis

Please provide your email address to receive an email when new articles are posted on . Patients with systemic sclerosis reported an improved ability to perform daily tasks when receiving ...
Business Wire

Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that the SENSCIS ® trial met its primary endpoint: reduction in the annual rate of decline in forced vital capacity (FVC a) in ...